Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities

Abstract

Background

Glucose abnormalities are frequent comorbidities influencing prognosis in patients with cardiovascular diseases. The objective of this study was to evaluate prognostic role of HbA1c in patients with acute myocardial infarction (AMI) treated invasively, who had newly detected glucose abnormalities.

Design

Single-centre registry encompassed 2146 survivors of AMI. In all patients without diabetes mellitus (DM), oral glucose tolerance test was performed before hospital discharge and interpreted according to the guidelines.

Methods

From the study population, two major groups with defined new glucose abnormalities and estimated HbA1c were selected: 457 patients with impaired glucose tolerance (IGT) and 306 patients with newly detected DM (newDM). In each of these groups, the median value of HbA1c was calculated and established as the cut-off point for further analysis. The median HbA1c for IGT group was 5.9% and for newDM was 7.0%.

Results

Patients with IGT and HbA1c ≤ 5.9% had significantly lower posthospital mortality (4.5%) than those with HbA1c >5.9% (25.0%; p<0.001). Similarly, patients with newDM and HbA1c ≤7.0% had lower mortality (6.4%) than those with HbA1c >7.0% (14.3%; p<0.05). Multivariate regression analysis revealed that increase of HbA1c was one of the strongest independent risk factors of death among IGT patients (HR 2.9, 95% CI 2.7–3.1; p < 0.001) and newDM (HR 1.53, 95% CI 1.39–1.66; p<0.05).

Conclusions

Increase of HbA1c in patients with newly detected glucose abnormalities was associated with significantly reduced survival after AMI treated invasively. Moreover, increase of HbA1c in patients with IGT and newDM was one of the strongest independent risk factors of death in these populations.

Keywords

Acute myocardial infarction diabetes mellitus HbA1c impaired glucose tolerance percutaneous coronary intervention

Get full access to this article

View all access options for this article.

References

Bartnik

Rydén

Ferrari

. Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880–1890.

Bartnik

Rydén

Malmberg

. Euro Heart Survey Investigators. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007; 93: 72–77.

Tamita

Katayama

Takagi

. Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations. Heart 2012; 98: 848–854.

Mazurek

Kowalczyk

Lenarczyk

. The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol 2012; 11: 78–78.

Pankow

Kwan

Duncan

. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30: 325–331.

Lazzeri

Valente

Chiostri

. Glycated hemoglobin in ST-elevation myocardial infarction without previously known diabetes: its short and long term prognostic role. Diabetes Res Clin Pract 2012; 95: e14–e16.

Timmer

Hoekstra

Nijsten

. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011; 124: 704–711.

Ishihara

Inoue

Kawagoe

. Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 2006; 27: 2413–2419.

Rydén

Mellbin

. Glucose perturbations and cardiovascular risk: challenges and opportunities. Diab Vasc Dis Res 2012; 9: 170–176.

10.

Anand

Dagenais

Mohan

. EpiDREAM Investigators. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012; 19: 755–764.

11.

Chan

. The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome. Clin Cardiol 2011; 34: 507–512.

12.

Britton

Aggarwal

Chen

. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J 2011; 161: 657–663.

13.

Stolker

Sun

Conaway

. Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus. Am J Cardiol 2010; 105: 1090–1094.

14.

Saleem

Mohammad

Abdel-Fattah

. Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease. Diab Vasc Dis Res 2008; 5: 184–189.

15.

Cakmak

Cetemen

. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can J Cardiol 2008; 24: 375–378.

16.

World Health Organization. Report of the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, Geneva: World Health Organization, 1999.

17.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 3(9): S1–S237.

18.

McCullough

Adam

Becker

. CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 9(8): 5K–13K.

19.

Gustafsson

Kistorp

James

. OPTIMAAL Study Group. Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. Am Heart J 2007; 154: 470–476.

20.

Rasoul

Ottervanger

Bilo

. Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: acute and chronic glucose dysregulation in STEMI. Neth J Med 2007; 65: 95–100.

21.

Tenerz

Nilsson

Forberg

. Basal glucometabolic status has an impact on long-term prognosis following an acute myocardial infarction in non-diabetic patients. J Intern Med 2003; 254: 494–503.

22.

van't Riet

Rijkelijkhuizen

Alssema

. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur J Prev Cardiol 2012; 19: 23–31.

23.

Stolar

. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010; 12(3): S3–S11.

24.

United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

25.

Selvin

Steffes

Zhu

. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800–811.

26.

Holman

Paul

Bethel

. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.

27.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

28.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643–2653.